Rating Change
Barclays analysts reiterated a Equal-Weight rating on Humana Inc. (NYSE:HUM) on July 31, 2026.
reiterateNYSE:HUM
Barclays Reiterates Equal-Weight Rating on Humana Inc. (HUM)
Rating Change Barclays analysts reiterated a Equal-Weight rating on Humana Inc. (NYSE:HUM) on July 31, 2026. Market Context Humana Inc.
Market Context
Humana Inc. operates in the Healthcare sector. The stock currently trades at $363.72 with a market capitalization of $32.0B. The stock has gained 55.4% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Humana Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Humana Inc.
Among the 10 most recent ratings: 3 Buy, 7 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 31, 2026 | TD Cowen | Hold | N/A |
| Jul 31, 2026 | Barclays | Equal-Weight | N/A |
| Jul 30, 2026 | Guggenheim | Buy | N/A |
| Jul 30, 2026 | Evercore ISI Group | Outperform | N/A |
| Jul 30, 2026 | Raymond James | Market Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View HUM Stock Page
Frequently Asked Questions
What does a Equal-Weight rating mean for HUM?
A Equal-Weight rating from Barclays reflects the analyst's outlook on Humana Inc. (NYSE:HUM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the HUM forecast page.
